ArticleCancer gene therapy2007

The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.

J Neukirchen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.